growth factor receptor (EGFR) to chemotherapy, 7 and the incorporation of other non-chemotherapy agents 8 all failed to improve survival and QOL. Recently, the addition of the anti–vascular endothelial growth factor (VEGF) antibody bevacizumab
Search Results
Maintenance Chemotherapy in Non–Small Cell Lung Cancer
Keith D. Eaton and Renato G. Martins
Oncology Research Program
Bevacizumab Added Concurrently to Chemotherapy for Palpable and Operable Triple-Negative Invasive Breast Cancer Principal Investigator: Jasgit C. Sachdev, MD Condition: Triple-negative breast cancer Institutions: University of Tennessee Cancer
Management of Advanced Ovarian, Fallopian Tube, and Primary Peritoneal Cancers
Presented by: Joyce F. Liu
benefit from bevacizumab? Is testing for homologous recombination deficiency (HRD)/genomic instability appropriate? What is the role of maintenance therapy with PARP inhibitors? Of note, because the treatment of advanced ovarian cancer is complex and
Oncology Research Program
Carboplatin Followed By Doxorubicin Plus Cyclophosphamide With Bevacizumab Added Concurrently to Chemotherapy for Palpable and Operable Triple Negative Invasive Breast Cancer Principal Investigator: Jasgit C. Sachdev, MD Condition: Triple negative breast
HSR21-065: Oncologists’ Perceptions and Utilization of Therapeutic Oncology Biosimilars in the U.S.
Sonia Oskouei, Amy Graham Russell, Yolaine Jeune-Smith, and Ajeet Gajra
critical therapies with the potential to lower cost of care. There are 9 FDA approved therapeutic oncology biosimilars to 3 reference molecules: trastuzumab (5), bevacizumab (2) and rituximab (2), in addition to supportive care biosimilars for hematopoietic
Management of Recurrent or Metastatic Cervical Cancer
Presented by: Nadeem R. Abu-Rustum
as bevacizumab and pembrolizumab is difficult in this patient population, because bevacizumab and pembrolizumab are not widely available, are expensive, and require specific expertise to be delivered. Despite their improved activity over traditional
HSR22-145: Pembrolizumab Plus Chemotherapy for First-Line Treatment of Advanced Triple-Negative Breast Cancer – A Network Meta-Analysis
Amin Haiderali, Min Huang, Wilbur Pan, Grace Fox, Dylan Maciel, and Andrew Frederickson
nab-paclitaxel for PFS. Statistical superiority was also reported for pembrolizumab+paclitaxel compared to paclitaxel (for OS and PFS), paclitaxel+ bevacizumab (for OS) and ixabepilone+bevacizumab (for OS). Conclusions : These analyses suggest
Advances in the Treatment of Non-Small Cell Lung Cancer
Leora Horn
guidelines, maintenance therapy is an option for select patients with tumor response or stable disease and is not considered the standard of care for all patients. Category 1 options in continuation maintenance therapy include single-agent bevacizumab and
Oncology Research Program
Bendamustine and Bevacizumab for Patients With Advanced Cancers Principal Investigator: Apostolia M. Tsimberidou, MD, PhD Condition: Advanced cancers Institution: The University of Texas MD Anderson Cancer Center, Houston, Texas Bendamustine is
Emerging Treatment Options for the Management of Metastatic Colorectal Cancer
Presented by: Dustin A. Deming
molecular features of the tumor. Across the continuum of treatment, patients usually received FOLFOX (5-FU/leucovorin/oxaliplatin) and/or FOLFIRI (5-FU/leucovorin/irinotecan) ± bevacizumab and an agent targeting the epidermal growth factor receptor (EGFR